Dr Reddy's outlook
"We expect Dr Reddy`s to post strong earnings growth led by launch of key products like Zyprexa, Allegra OTC, Geodon & Fondaparinux."
"Also products like Fondaparinux, Allegra & Exelon will drive the growth in US for Dr Reddys."
http://www.myiris.com/newsCentre/storyShow.php?fileR=20120403185233200&dir=2012/04/03&secID=livenews
"Dr Reddy
Dr. Reddy`s revenue performance will be majorly driven by Zyprexa exclusivity & traction in Fondaparinux sales."
http://www.myiris.com/newsCentre/storyShow.php?fileR=20120403185227200&dir=2012/04/03&secID=livenews
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable